Literature DB >> 3499946

Flow cytometric analysis of T-lymphocyte subpopulations in B-cell chronic lymphocytic leukemia: correlation with clinical stage.

M L Hautekeete1, R F De Bock, D R Van Bockstaele, G C Colpin, Z N Berneman, M E Peetermans.   

Abstract

Several authors have studied the T-lymphocyte subpopulations in B-cell chronic lymphocytic leukemia (B-CLL), but previous studies were performed after preceding enrichment procedures, which are known to cause selective losses of certain subpopulations. To correct for this deficiency we used flow cytometric analysis, which enabled us to measure subpopulations directly on total blood samples. We studied T-lymphocyte subsets with OKT monoclonal antibodies in 45 patients with B-CLL. Serum levels of IgG, IgA and IgM were assayed simultaneously and findings were correlated with clinical stage (Rai classification). The absolute number of CD4-positive cells decreased in more advanced Rai stages, while the absolute number of CD8-positive cells increased, resulting in a progressive reduction in CD4/8 ratio. Results from patients in stages with equal prognosis (Rai I and II, Rai III and IV) were similar and when these results were grouped the observed differences were highly significant and clearly correlated with all prognostic groups.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499946     DOI: 10.1007/BF00367462

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  19 in total

1.  Suppressor T cells in B-cell chronic lymphocytic leukaemia: relationship to clinical stage.

Authors:  K H Mills; J C Cawley
Journal:  Leuk Res       Date:  1982       Impact factor: 3.156

2.  Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies.

Authors:  C D Platsoucas; M Galinski; S Kempin; L Reich; B Clarkson; R A Good
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

3.  A rapid micromethod for evaluating T cell subsets in blood using monoclonal antisera.

Authors:  I H Frazer; I R Mackay
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

4.  Further evidence for T cell abnormalities in chronic lymphocytic leukaemia of the B cell type.

Authors:  F Herrmann; G Sieber; Z Chen; B Enders; B Komischke; H Rühl
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

5.  Increase in T gamma lymphocytes in B-cell chronic lymphocytic leukaemia. II. Correlation with clinical stage and findings in B-prolymphocytic leukaemia.

Authors:  D Catovsky; F Lauria; E Matutes; R Foa; V Mantovani; S Tura; D A Galton
Journal:  Br J Haematol       Date:  1981-04       Impact factor: 6.998

6.  Unusual T-cell phenotype in advanced B-chronic lymphocytic leukaemia.

Authors:  E Matutes; A Wechsler; R Gomez; M Cherchi; D Catovsky
Journal:  Br J Haematol       Date:  1981-12       Impact factor: 6.998

7.  T-lymphocyte subpopulations in chronic lymphocytic leukemia: a quantitative and functional study.

Authors:  G Semenzato; A Pezzutto; C Agostini; M Albertin; G Gasparotto
Journal:  Cancer       Date:  1981-11-15       Impact factor: 6.860

8.  Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type.

Authors:  F Herrmann; A Lochner; H Philippen; B Jauer; H Rühl
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

9.  Clinical staging and immunological findings in chronic lymphocytic leukemia.

Authors:  R Foa; D Catovsky; M Brozovic; G Marsh; T Ooyirilangkumaran; M Cherchi; D A Galton
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

10.  Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia.

Authors:  G Pizzolo; M Chilosi; A Ambrosetti; G Semenzato; L Fiore-Donati; G Perona
Journal:  Blood       Date:  1983-12       Impact factor: 22.113

View more
  1 in total

1.  Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia.

Authors:  A Leenders; P Sonneveld; S de Marie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.